AEMDAEMDHealthcare · Medical Devices

AEMD Stock Forecast: Aethlon Medical, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$5.46

The median 12-month analyst price target for Aethlon Medical, Inc. is $13. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$8.8M
Ticker Nerd rank
24/ 100
Median analyst target
$13
Analysts covering
2
Revenue$0.0
Operating income−$1.9M
Net income−$1.9M
Free cash flow−$1.8M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Aethlon Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
24/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
79
Issuance
41
Revisions
36
Momentum
36
Volatility
33
Growth
28
Quality
10
Value
8

Accruals (79): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AEMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AEMD, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts
0
Buy
2
Hold
0
Sell
$2
Low
$13
Median
$25
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2025HC Wainwright & Co.ReiteratesNeutral$1.50
7 July 2025HC Wainwright & Co.AssumesNeutral$1.50
10 Mar 2025HC Wainwright & Co.ReiteratesBuy—
19 Feb 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 June 2024HC Wainwright & Co.MaintainsBuy—
4 Mar 2024HC Wainwright & Co.MaintainsBuy—
24 Oct 2023HC Wainwright & Co.MaintainsBuy—
15 Nov 2022Maxim GroupDowngradeHold—
25 June 2021HC Wainwright & Co.MaintainsBuy$5.00 → $9.00
1 June 2021HC Wainwright & Co.InitiatesBuy—
8 Jan 2021Maxim GroupInitiatesBuy—
25 Nov 2020H.C. WainwrightInitiatesBuy—
20 Nov 2017H.C. WainwrightInitiatesBuy—
20 Nov 2017HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AEMD.

Market Radar

This page is one stock. Monday covers all of them.

AEMD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

AEMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.4×

Cheaper than 55% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−136.8%

Higher than 11% of US stocks

Return on assets
−70.3%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aethlon Medical, Inc. has a market value of $8.8M and an enterprise value of $2.5M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$7.2M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$7.0M.

  • Shares outstanding: 1.6M.

  • Aethlon Medical, Inc. employs 9 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

AEMD and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
AEMDAethlon Medical, Inc.$8.8M24
PAVMPAVmed, Inc.$9.1M31
SINTSINTX Technologies, Inc.$8.3M41
LFWDLifeward Ltd.$7.9M15
IRIXIRIDEX Corp.$7.6M47
HSCSHeartSciences, Inc.$10.3M43
ITOCiTonic Holdings Ltd.$11.6M15

Take a look at AEMD’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Aethlon Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about AEMD

What is the AEMD stock price forecast for 2026-2027?

The median 12-month analyst price target for Aethlon Medical, Inc. is $13, with estimates ranging from $1.5 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AEMD stock a buy right now?

Of the 2 analysts covering Aethlon Medical, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aethlon Medical, Inc. 24 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AEMD?

As at 21 Nov 2026, Aethlon Medical, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (79 of 100).

Will AEMD stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $13, and Ticker Nerd's factor model ranks Aethlon Medical, Inc. 24 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AEMD stock forecast for 2030?

No analyst covering Aethlon Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AEMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $25 over the next 12 months.

What does Aethlon Medical, Inc. do?

Aethlon Medical, Inc. is a medical therapeutic company focused on developing immunotherapeutic technologies for oncology and infectious disease. Its lead product, the Hemopurifier, is a clinical-stage extracorporeal device designed to remove circulating disease-related targets from blood and other biologic fluids.

Company

About Aethlon Medical, Inc.

Aethlon Medical, Inc. is a medical therapeutic company focused on developing immunotherapeutic technologies for oncology and infectious disease. Its lead product, the Hemopurifier, is a clinical-stage extracorporeal device designed to remove circulating disease-related targets from blood and other biologic fluids. The company’s work spans applications in cancer care, life-threatening viral infections, and organ transplantation, with a broader emphasis on addressing unmet needs in medical treatment and biodefense. Aethlon Medical combines device-based therapy and filtration science to support clinical research in areas where current options remain limited. Headquartered in San Diego, California, the company operates as a specialized player in the healthcare sector, concentrating on advanced therapeutic devices rather than broad pharmaceutical products.

CEO Mr. James B. Frakes M.B.A. · 9 employees · United States · https://www.aethlonmedical.com